Get started

Course

MRK Merck On the Verge of a Breakout? Unusual Calls !!Merck (MRK) is setting up for what could be a high-probability breakout. The stock has been in a falling wedge pattern for several months — a classic technical formation that often precedes sharp upside moves. Price action has now compressed to the end of the wedge, and we may be on the brink of a bullish resolution. 🔍 Technical Setup Falling Wedge Pattern nearing completion Price currently hovering near long-term support ($78.25) Strong bullish divergence forming on momentum indicators (RSI/MACD) The falling wedge is typically a reversal pattern, and given how deep MRK has pulled back from its highs ($134+), the risk/reward here looks compelling. 🔥 Options Flow Today’s options market added fuel to the fire: 48,000 call contracts traded expiring this Friday This sudden surge in short-dated call buying signals aggressive positioning for an imminent move This kind of volume is not retail-driven — it points to potential institutional interest 💡 The Bullish Case With the technical breakout structure in place and strong confirmation from options flow, the case for a bullish reversal is growing. If MRK can close above wedge resistance with volume, it opens the door to a quick move toward $85+, possibly even higher in the coming weeks. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:MRKLong
by TopgOptions
Bullish Thesis for INTC Intel Stock in 2025If you haven`t bought INTC before the previous earnings: Now Intel INTC is positioned for a potential turnaround and upside by the end of 2025, driven by strategic leadership changes, foundry business expansion, AI innovation, and favorable geopolitical dynamics. Here’s why INTC could head higher this year: 1. Leadership Transformation and Strategic Vision The appointment of Lip-Bu Tan as CEO in March 2025 has injected new optimism into Intel’s prospects. Tan is a respected semiconductor industry veteran, and his arrival was met with a 10% jump in INTC’s share price, reflecting renewed investor confidence in the company’s direction. 2. Foundry Business Expansion and Government Support Intel’s pivot toward a foundry-centric model is gaining momentum. The company is leveraging its U.S.-based manufacturing footprint to attract domestic and international clients, especially as geopolitical tensions and trade restrictions make U.S. chip production more attractive. There is speculation about strategic partnerships, such as TSMC potentially acquiring a stake in Intel’s foundry operations, which could accelerate technology transfers and client wins. The U.S. government is likely to continue supporting domestic semiconductor manufacturing through incentives and tariffs, directly benefiting Intel’s foundry ambitions. 3. AI and Next-Gen Product Launches Intel is aggressively targeting the AI and data center markets. The upcoming Jaguar Shores and Panther Lake CPUs, built on the advanced 18A process node, are set for release in the second half of 2025. These chips will be available not only for Intel’s own products but also for external clients like Amazon and Microsoft, expanding the addressable market. Intel’s renewed focus on AI accelerators and competitive cost structures could help it regain share in high-growth segments. 4. Financial Resilience and Market Position Despite recent setbacks, Intel remains a dominant player in the PC CPU market and continues to generate substantial revenue, outpacing some key competitors in the latest quarter. Analysts have revised their short-term price targets upward, with some projecting INTC could reach as high as $62—a potential upside of over 170% from current levels. Forecasts for 2025 suggest an average price target in the $40–$45 range, with bullish scenarios pointing even higher if execution on foundry and AI strategies meets expectations. 5. Technical and Sentiment Factors While technical analysis currently signals caution, the $18.50–$20 zone has provided strong support, and any positive news on foundry contracts or AI wins could catalyze a breakout from current consolidation patterns. Market sentiment has shifted more positively following the CEO change and strategic announcements, suggesting the potential for a sustained rebound if Intel delivers on its promises. In conclusion: Intel’s combination of visionary leadership, foundry expansion, AI innovation, and favorable geopolitical trends sets the stage for a potential stock price recovery by the end of 2025. With analyst targets and investor sentiment turning more bullish, INTC presents a compelling case for upside as it executes its turnaround strategy Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:INTCLong
by TopgOptions
AAOI Applied Optoelectronics potential rally by EOYApplied Optoelectronics AAOI is well-positioned for a strong rally toward $24 per share by the end of 2025, supported by multiple operational and strategic catalysts. A key recent development—the warrant agreement with Amazon—adds a powerful endorsement and financial backing that enhances the bullish case. 1. Amazon’s Strategic Warrant Agreement: A Major Vote of Confidence On March 13, 2025, AAOI issued a warrant to Amazon.com NV Investment Holdings LLC, granting Amazon the right to purchase up to approximately 7.95 million shares at an exercise price of $23.70 per share. About 1.3 million shares vested immediately, with the remainder vesting based on Amazon’s discretionary purchases, potentially up to $4 billion in total purchases over time. This agreement signals Amazon’s strong confidence in AAOI’s technology and its critical role as a supplier of high-speed optical transceivers for Amazon Web Services and AI data center infrastructure. The warrant price near $24 effectively sets a floor and a valuation benchmark, supporting the thesis that AAOI’s stock could reach or exceed this level by year-end. 2. Major Data Center Wins and Hyperscale Customer Re-Engagement AAOI recently resumed shipments to a major hyperscale customer, with volume shipments of high-speed data center transceivers expected to ramp significantly in the second half of 2025. This re-engagement with a key customer aligns with the surging demand for AI-driven data center infrastructure, providing a strong revenue growth catalyst. 3. Robust Revenue Growth and Margin Expansion Q1 2025 revenue doubled year-over-year to nearly $100 million, with gross margins expanding to over 30%, reflecting operational efficiencies and favorable product mix. The company expects to sustain strong quarterly revenue ($100–$110 million) and ramp production capacity to over 100,000 units of 800G transceivers per month by year-end, with 40% manufactured in the U.S. 4. Manufacturing Expansion and Supply Chain Resilience AAOI is scaling manufacturing in the U.S. and Taiwan, enhancing supply chain robustness and positioning itself to benefit from potential government incentives for domestic production. Its automated, largely in-house manufacturing capabilities provide a competitive edge in meeting hyperscale and AI data center demand. In conclusion: Amazon’s warrant agreement at a $23.70 strike price not only provides a direct valuation anchor near $24 but also serves as a powerful strategic endorsement of AAOI’s technology and growth prospects. Combined with robust revenue growth, expanding manufacturing capacity, and key customer re-engagement, AAOI has a compelling case to reach or exceed $24 per share by the end of 2025.
NASDAQ:AAOILong
by TopgOptions
VKTX Viking Therapeutics Potential Buyout Soon?!If you haven`t bought VKTX before the previous rally: If GLP-1 obesity drugs are a multi-hundred-billion-dollar opportunity, a successful VK2735 (injectable + oral) could justify a valuation far north of where VKTX trades today—if it makes it to market. My bullish thesis: 1. GLP-1 Momentum + “Mini Lilly / Novo” Narrative VKTX is seen as a “pure play” on the global obesity and metabolic-disease boom. Viking’s lead program, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both injectable and oral form for obesity and related metabolic disorders. Phase 1 and Phase 2 data for the injectable version have already shown meaningful weight loss with an encouraging safety/tolerability profile, which is why it advanced into large Phase 3 obesity trials. An oral version of VK2735 is in Phase 2 obesity trials and, in the VENTURE oral study, delivered up to ~12.2% mean weight loss at 13 weeks, with a clear dose response. 2. Rapid Trial Execution = Strong Momentum & Upcoming Catalysts Another big talking point is how fast Viking is executing on its trials, which bulls see as a leading indicator of future news flow: Viking recently announced completion of enrollment in its Phase 3 VANQUISH-1 VK2735 obesity trial, with ~4,650 patients (above the original 4,500 target). The company highlighted VK2735 data at ObesityWeek 2025 and continues to position both injectable and oral formulations as core programs. Management has reiterated that VK2735 oral and injectable programs are moving forward on schedule, with more data expected as Phase 3 and longer-duration studies mature. 3. Short Interest + “Squeeze Fuel” Angle VKTX has a high short interest, which Twitter traders love to highlight: Recent data shows around 22–23% of the float short, with days to cover >5 based on average volume. For many momentum and options traders, this is exactly the kind of setup they look for: High short interest = a lot of investors betting against the stock. Any positive surprise (trial data, partnership, M&A rumor, or a strong breakout on the chart) could force shorts to cover. If that happens during a period of high retail interest, the price action can get violent to the upside. 4. Analyst Targets + Big Pharma Takeover Speculation Analyst consensus is currently Strong Buy, with an average price target around $95+. On top of that, there’s constant speculation that VKTX could become a takeover target: The GLP-1 market is being dominated by Eli Lilly (Zepbound, Mounjaro) and Novo Nordisk (Wegovy, Ozempic). Many large pharma companies without a strong obesity franchise might prefer buying a late-stage asset rather than starting from scratch. VK2735, with Phase 3 obesity trials underway and promising oral data, is the kind of asset that fits that narrative.
NASDAQ:VKTXLong
by TopgOptions
BTC Bitcoin Bear Market If you haven`t bought BTC before the recent rally: Historically, Bitcoin has shown a tendency to retrace in December before starting a recovery around March. This pattern could repeat this season, with BTC facing selling pressure as year-end portfolio rebalancing and macro uncertainties weigh on the market. While a brief Santa Claus rally might provide temporary relief, the bearish trend is expected to dominate until March. By then, BTC could trade below $84K before regaining momentum, aligning with its historical recovery trend as market conditions stabilize in spring.
Short
by TopgOptions
Warning Signs Flashing: SPY May Plunge After Earnings SeasonAfter the recent rollercoaster in equities and crypto, markets are entering a critical period: earnings season. While the initial rebound after last Friday’s selloff has restored some optimism, the broader picture suggests potential downside for SPY in the weeks ahead. Earnings Season: A Stress Test for Stocks The third-quarter earnings season kicks off with major banks and tech companies reporting this week. Expectations are high: analysts project around 8% EPS growth for S&P 500 constituents. However, several factors indicate that this season could reveal underlying weaknesses: High expectations and valuation pressure – Companies that fail to meet earnings or guidance could see outsized declines, creating ripple effects across the index. Sectoral stress – Technology, finance, and industrials are exposed to higher input costs, slowing consumer demand, and margin compression. Misses in these sectors often drive SPY lower more than average. Macro headwinds – High interest rates, slowing GDP growth, and trade tensions with China could exacerbate negative reactions. Historically, SPY tends to be vulnerable after earnings seasons that reveal cracks in corporate performance, especially when macro uncertainty is elevated. Geopolitical and Macroeconomic Pressures Trade tensions: The U.S.-China conflict over rare earth metals and tariffs adds uncertainty to corporate supply chains. Even if earnings beat expectations, investor sentiment can remain fragile. Recession risk: Economists from J.P. Morgan and S&P Global highlight a 30–40% chance of a U.S. recession by year-end 2025. Weak economic indicators can amplify post-earnings selloffs. Volatility spikes: The VIX has started creeping higher after last week’s recovery, signaling that investors are hedging against downside risks. Historically, spikes in VIX correlate with short-term SPY declines. Conclusion: Post-Earnings Risk for SPY Traders and investors should watch for: Missed earnings or cautious guidance from major banks and tech companies. Rising VIX and fear-driven flows into protective options. Breaks of critical technical support levels in SPY. In this environment, positioning for a modest correction or increased volatility in SPY could be prudent until the earnings season clears and market sentiment stabilizes.
AMEX:SPYShort
by TopgOptions
1
BABA Alibaba Group Holding Limited Options Ahead of EarningsIf you haven`t bought the dip on BABA: Now analyzing the options chain and the chart patterns of BABA Alibaba Group Holding Limited prior to the earnings report this week, I would consider purchasing the 135usd strike price Calls with an expiration date of 2025-9-19, for a premium of approximately $14.25. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
NYSE:BABALong
by TopgOptions
2
SPY S&P 500 etf Oversold on the RSI ! 2025 Price Target ! The SPDR S&P 500 ETF Trust (SPY) is flashing a major buy signal, with its Relative Strength Index (RSI) currently sitting at 28.33 — firmly in oversold territory. Historically, every time SPY has entered oversold levels on the RSI, institutional buyers have stepped in aggressively, driving sharp rebounds in the following weeks and months. The last time SPY dipped below the 30 RSI threshold was during market pullbacks in 2022 and 2023 — both of which were followed by significant rallies as institutions capitalized on discounted valuations. The current setup is no different. With earnings growth stabilizing, inflation cooling, and the Federal Reserve signaling a potential shift toward rate cuts in the second half of the year, the backdrop for a recovery is aligning perfectly. Technically, SPY is also approaching key support levels that have held strong in past market corrections. The combination of an oversold RSI and strong institutional appetite at these levels creates a compelling case for a bounce. My price target for SPY by year-end is $640, representing over 15% upside from current levels. With sentiment stretched to the downside and technical indicators flashing green, SPY looks primed for a sharp and sustained rebound. Now could be the perfect time to position for the next leg higher.
AMEX:SPYLong
by TopgOptions
2